Related Experiment Video
Updated: Jun 4, 2025

06:35
Basics of Multivariate Analysis in Neuroimaging Data
Published on: July 24, 2010
16.8K
A Multiform Heterogeneity Framework for Alzheimer's Disease Based on Multimodal Neuroimaging
Kun Zhao1, Pindong Chen2, Dong Wang3
1School of Artificial Intelligence, Beijing University of Posts and Telecommunications, Beijing, China; Queen Mary School Hainan, Beijing University of Posts and Telecommunications, Hainan, China.
Biological Psychiatry
|December 26, 2024
Summary
This review explores Alzheimer's disease (AD) heterogeneity using neuroimaging. It organizes current methods to improve personalized AD treatments and bridge the gap between research and clinical practice.
Area of Science:
- Neuroscience
- Medical Imaging
- Neurology
Background:
- Understanding Alzheimer's disease (AD) heterogeneity is vital for precision medicine.
- Existing neuroimaging frameworks face challenges in translating AD heterogeneity insights from research to clinical practice.
Purpose of the Study:
- To systematically review and organize data-driven neuroimaging methodologies for Alzheimer's disease heterogeneity.
- To evaluate current approaches based on pathology understanding and clinical applicability.
- To identify limitations and future directions for enhancing AD neuroimaging heterogeneity frameworks.
Main Methods:
- Systematic review of prior studies on data-driven neuroimaging for AD heterogeneity.
- Organization of methodologies into subtyping, stratification, and individual-specific pattern analysis.
- Evaluation of studies based on pathology understanding and clinical application.
Main Results:
- Methodologies were categorized into patient subtyping (cross-sectional and longitudinal), biomarker-integrated stratification, and normative modeling for individual patterns.
- Current studies were assessed for their depth in understanding AD pathology and their clinical utility.
- Key limitations and challenges in the field were identified.
Conclusions:
- Enhanced neuroimaging heterogeneity frameworks are needed to advance precision medicine for Alzheimer's disease.
- Bridging the gap between bench and bedside requires addressing current methodological limitations.
- Future research should focus on refining these frameworks for better clinical translation.

